Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01753804 · ClinicalTrials.gov registry record
A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Terminated
- Registry status
- 269
- Enrollment target
NCT01753804 is a clinical trial that was terminated before completion, run by BioMarin Pharmaceutical. The registered enrollment target is 269 participants.
The verdict
NCT01753804 was terminated before completion, sponsored by BioMarin Pharmaceutical.
- TERMINATED
- Registry status
- 269 participants
- Enrollment target
Study Summary
To characterize the natural history and progression of Duchenne Muscular Dystrophy (DMD) to help inform the design of future studies, to capture biomarkers of safety and disease progression and to provide comparative data for the development of rare exons for which formal controlled trials are not feasible.
Interventions
- OTHER Observational study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2012-09-01 |
| Est. Completion | 2016-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01753804
The ClinicalTrials.gov registry entry for NCT01753804 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 269 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Observational study is the first listed.
NCT01753804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01753804 about?
NCT01753804 is a clinical study titled "A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.". To characterize the natural history and progression of Duchenne Muscular Dystrophy (DMD) to help inform the design of future studies, to capture biomarkers of safety and disease progression and to provide comparative data for the development of rare exons for which formal controlled trials are not f...
What is the current status of trial NCT01753804?
This trial is currently terminated. The enrollment target is 269 participants. The study started on 2012-09-01. Estimated completion is 2016-10-01.
What interventions are being tested in trial NCT01753804?
The interventions under investigation include: Observational study (OTHER).
Who is sponsoring clinical trial NCT01753804?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.